` THTX (Theratechnologies Inc) vs S&P 500 Comparison - Alpha Spread

THTX
vs
S&P 500

Over the past 12 months, THTX has significantly outperformed S&P 500, delivering a return of +132% compared to the S&P 500's +16% growth.

Stocks Performance
THTX vs S&P 500

Loading
THTX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
THTX vs S&P 500

Loading
THTX
S&P 500
Difference
www.alphaspread.com

Performance By Year
THTX vs S&P 500

Loading
THTX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Theratechnologies Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Theratechnologies Inc
Glance View

Market Cap
155.9m USD
Industry
Biotechnology

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

THTX Intrinsic Value
4.36 USD
Undervaluation 22%
Intrinsic Value
Price
Back to Top